Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Merck
Cipla
Deloitte
Colorcon
Cerilliant
Moodys
Citi
UBS

Generated: December 18, 2018

DrugPatentWatch Database Preview

Levomilnacipran hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for levomilnacipran hydrochloride and what is the scope of levomilnacipran hydrochloride freedom to operate?

Levomilnacipran hydrochloride is the generic ingredient in one branded drug marketed by Allergan Sales Llc and is included in one NDA. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Levomilnacipran hydrochloride has fifty-four patent family members in twenty-seven countries.

There are ten drug master file entries for levomilnacipran hydrochloride. One supplier is listed for this compound.

Pharmacology for levomilnacipran hydrochloride
Synonyms for levomilnacipran hydrochloride
(+)-(1S,2R)-MILNACIPRAN
(+)-Milnacipran
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
(1S-cis)-Milnacipran Hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
(1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
(1S,2R)-2-Aminomethyl-1-phenyl-cyclopropanecarboxylic acid diethylamide
(1S,2R)-milnacipran
(1S,2R)-Milnacipran Hydrochloride
101152-94-7
152M947
175131-60-9
371U2ZK31U
96847-54-0
AC1OCEN6
AC1OCEN8
AK481450
AKOS025311514
API0003393
AS-12868
AT-28508
BDBM50032379
C15H22N2O.HCl
CCG-231710
CHEBI:136040
CHEMBL2105732
CHEMBL99946
cis-(+)-Milnacipran Hydrochloride
cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
CS-4972
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (1S,2R)-
D02XOK
D10072
D10133
Dalcipran
DB08918
F 2695
F 2695 hydrochloride
F-2207
F-2695
f2-695
F2695
Fetzima
Fetzima (TN)
GJJFMKBJSRMPLA-DZGCQCFKSA-N
GTPL7435
HY-B0168B
Ixel
J10386
Joncia
K-0218
Levomilnacipran
Levomilnacipran (USAN/INN)
Levomilnacipran [USAN:INN]
Levomilnacipran HCl
Levomilnacipran hydrochloride (USAN)
Levomilnacipran hydrochloride [USAN]
M2133
MFCD00901293
MFCD18433402
Midalcipran hydrochloride
Milnacipram
Milnacipran ((1S-cis) hydrochloride)
Milnacipran (1S-cis) hydrochloride
Milnacipran HCl
Milnacipran hydrochloride
Milnacipran Hydrochloride 1.0 mg/ml in Methanol (as free base)
MolPort-019-939-251
Savella
SCHEMBL1148742
SCHEMBL1414867
TN-912
Toledomin
UGM0326TXX
UNII-371U2ZK31U
UNII-G56VK1HF36 component GJJFMKBJSRMPLA-DZGCQCFKSA-N
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-NQQJLSKUSA-N
UNII-UGM0326TXX
ZINC506

US Patents and Regulatory Information for levomilnacipran hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-003 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-004 Jul 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-004 Jul 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-003 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Merck
Cipla
Deloitte
Colorcon
Cerilliant
Moodys
Citi
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.